ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R01AD12 | B | Fluticasone furoate - 27.5mcg/dose | 11160 | 76221/1 | AVAMYS | 27.5mcg/dose | 120 doses | Suspension | Nasal | Abela Frères S.A.L. | Glaxo Wellcome SA | Spain | 722,987 L.L | 23.08 | A2 | GlaxoSmithKline Australia Pty Ltd | Australia | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R01AD12 | B | Fluticasone furoate - 27.5mcg/dose | 5980 | 218766/09 | AVAMYS | 27.5mcg/dose | 120 doses | Suspension | Nasal | Abela Frères S.A.L. | Glaxo Operations UK Ltd | UK | 722,987 L.L | 23.08 | A2 | Glaxo Operations UK Ltd | UK | 2/5/2024 | 0 |